Polyethyleneimine (PEI) is a versatile non-viral vector with strong cell adhesion, capable of transfecting cells without lysosomal inhibitors. PEI binds DNA via electrostatic forces, forming compact, positively charged PEI-DNA complexes that interact with cell membranes and are taken up by endocytosis. However, PEI's positive charge can damage cells, posing toxicity challenges for gene delivery. Yeasen Biotechnology uses AI-driven molecular dynamics and docking to design novel PEI derivatives with enhanced activity, stability, and safety. This advanced gene delivery tool overcomes the limitations of traditional PEI by reducing cytotoxicity and boosting transfection efficiency.
Figure 1. Structure of Linear PEI.
The Science: How PEI Works
To understand our breakthrough, it is essential to understand the mechanism of Linear PEI. Its structure, characterized by a high density of nitrogen atoms, allows it to interact effectively with negatively charged nucleic acids (DNA/RNA).
- Complex Formation: PEI binds to nucleic acids via electrostatic forces, forming compact complexes that protect the genetic material from nuclease degradation.
- Cellular Uptake: The positive charge of the complex attracts it to the cell membrane, facilitating uptake via endocytosis.
- The Proton Sponge Effect: Once inside the cell, the acidic environment of the endosome triggers PEI to absorb protons. This influx causes counterions and water to enter the endosome, increasing osmotic pressure until the membrane ruptures, releasing the nucleic acid into the cytoplasm.
The Challenge: While effective, the high cationic charge density that drives this process can also damage cell membranes and intracellular structures, leading to cytotoxicity.
The Yeasen Innovation: AI-Driven Molecular Design
To address the toxicity-efficiency trade-off, Yeasen Biotechnology leveraged advanced technology platforms, including AI-driven molecular dynamics simulations and molecular docking techniques.
This computational approach allowed us to screen and design novel PEI derivatives at the molecular level. Through high-throughput screening and structural optimization, we identified lead compounds that maintain the "proton sponge" capability while minimizing harm to the cell.
Figure 2. Screening of Modified Molecules for Hieff Trans™ Novel Transfection Reagents
Key Benefits of the New Yeasen PEI Derivative
Our advanced gene delivery tool represents a significant step forward in transfection technology.
Reduced Toxicity: By carefully lowering the cationic density, we minimize damage to the cell membrane, offering a safer delivery vehicle suitable for sensitive applications.
- High Stability: Unique structural modifications introduce hydrogen bonding alongside electrostatic interactions. This dual-force approach enhances the stability of the PEI/nucleic acid complex, ensuring reliable transfection.
- Improved Transfection Efficiency: The new derivative incorporates hydrophobic properties that promote fusion with the cell membrane. This results in higher cell viability and superior AAV production yields.
- Cost-Effectiveness: Optimized performance means you can achieve high yields with greater consistency, significantly reducing the overall cost of your experiments.
Mechanism of Action
The newly developed PEI variant is not just a chemical tweak; it is a re-engineered vector.
Figure 3. Illustration of mechanism of novel PEI-AAV.
The structural design features specific modification groups that enhance the fusion of the transfection complex with the cell membrane. This promotes efficient uptake and release. These dual modifications—reduced cationic density combined with enhanced hydrophobicity and hydrogen bonding—create a vector that is stable, biocompatible, and highly efficient.
UltraAAV Transfection Reagent (40823ES & 40824ES)
Key Features:
- High Viral Yield: Achieves viral titers up to 10¹² Vg/mL with a two-fold increase in full-particle ratio
- Reduced Usage: Half the amount of transfection reagent required, without compromising virus yield
- Broad Applicability: Suitable for production of multiple AAV serotypes (e.g., AAV2/5/6/8/9)
- Compliant with US/China IND Submissions: Manufactured under GMP standards with DMF filing available and quality management per ISO 13485
- Regulatory-Ready: DMF filed to meet requirements for drug development submissions
Performance
Half the Reagent, Same Viral Titer
Figure 4. Transfection Performance Comparison
Yeasen’s next-generation PEI AAV transfection reagent achieves higher viral yield than Company P using only half the reagent, cutting transfection reagent costs by 50% for the same viral output.
Viral Yield & Viability Doubled
Figure 5. AAV9 and AAV5 Project Validation
AAV9 and AAV5 packaging performance comparison between Yeasen’s transfection reagents and Company P. For AAV9(A/B), Yeasen’s PEI AAV Transfection Reagent achieved markedly higher viral yield and particle integrity at DNA-to-reagent ratios of 1:0.5 and 1:1. In the AAV5 project(C/D), Yeasen UltraAAV Transfection Reagent maintained superior viral titer and capsid integrity even when used at only half the amount of Company P.
Strong Stability
Figure 6. Stability evaluation in the AAV9 project.
Hieff Trans™ demonstrated consistent performance across three GMP-grade batches and passed both accelerated and transport stability testing, ensuring reliable and stable supply.
Through advanced molecular design, our novel PEI derivative transcends the cytotoxicity limitations of traditional linear PEI, delivering significant improvements in both transfection efficiency and biocompatibility. By enhancing complex stability and membrane fusion, this formulation meets the rigorous demands of AAV production, achieving higher viral yields with reduced toxicity. This breakthrough not only empowers biomedical research but also establishes a safer, more effective foundation for next-generation gene therapies. Upgrade your gene delivery systems today to maximize efficiency and biocompatibility!
Related Products
|
Product |
Product Number |
Size |
|
Polyethylenimine Linear(PEI) MW 25000 |
40815ES03/08 |
1 g / 5×1 g |
|
40816ES02/03 |
100 mg / 1 g |
|
|
40819ES01/03/10/60 |
100 μL / 1 mL / 10 mL / 100 mL |
|
|
40823ES03/10/60 |
1 mL / 10 mL / 100 mL |
|
|
40824ES10/60/80 |
10 mL / 100 mL / 1 L |